Chronic hemodialysis patients with visceral obesity have a higher risk for cardiovascular events

Yukie Moriyama1, Rieko Eriguchi, Yuzuru Sato

  • 1Depertment of Nutrition and Health Promotion, Hiroshima Jogakuin University, 4 - 13 - 1, Ushita Higashi, Higashi-ku Hiroshima 7320063, Japan. myuki92@mocha.ocn.ne.jp

Insights

Increased visceral fat area in hemodialysis patients is linked to higher cardiovascular complications and ischemic heart disease risk. This finding highlights abdominal obesity as a critical factor in vascular events for dialysis patients.

Area of Science:

  • Nephrology
  • Cardiology
  • Radiology

Background:

  • Cardiovascular disease (CVD) poses a significant risk to hemodialysis patients.
  • Established CVD risk factors in dialysis patients include age, malnutrition, dialysis duration, diabetes mellitus, and hyperphosphatemia.
  • The association between abdominal obesity and CVD in dialysis patients remains unclear.

Purpose of the Study:

  • To investigate the relationship between visceral fat area and cardiovascular complications in chronic dialysis patients.
  • To determine if visceral fat area is an independent risk factor for cardiovascular events in this population.

Main Methods:

  • Visceral fat area was quantified using computed tomography (CT) scans in 94 chronic dialysis patients.
  • Abdominal aortic calcification index (ACI), serum lipid profiles (triglyceride, HDL-cholesterol), and cardiovascular disease complications were assessed.
  • Patients were categorized based on visceral fat area (<100 cm² vs. ≥100 cm²).

Main Results:

  • Patients with larger visceral fat area (≥100 cm²) exhibited significantly higher rates of cardiovascular complications.
  • Higher visceral fat area was associated with elevated serum triglyceride levels and reduced HDL-cholesterol levels.
  • Larger visceral fat area, particularly when combined with longer dialysis duration, correlated with more severe aortic calcification (ACI) and increased incidence of ischemic heart disease.

Conclusions:

  • Elevated visceral fat area is a significant risk factor for cardiovascular events in chronic dialysis patients.
  • Abdominal obesity, indicated by visceral fat area, contributes to the high cardiovascular risk observed in hemodialysis populations.
  • Targeting visceral fat may be crucial for mitigating vascular event risk, especially ischemic heart disease, in hemodialysis patients.

Related Concept Videos

Hemodialysis II: Procedure and Complications01:24

Hemodialysis II: Procedure and Complications

DialyzersA hemodialysis (HD) dialyzer is a plastic cartridge containing thousands of parallel hollow fibers, which serve as semipermeable membranes. These fibers are typically made from cellulose-based or other synthetic materials. During HD, blood is pumped into the top of the cartridge and distributed among these fibers. Simultaneously, dialysis fluid, known as dialysate, is introduced into the bottom of the cartridge, bathing the outside of the fibers. Across the semipermeable membrane,...
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
Cholesterol: Significance and Regulation01:29

Cholesterol: Significance and Regulation

Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Hemodialysis I: Introduction01:25

Hemodialysis I: Introduction

Hemodialysis (HD) is a medical treatment that artificially removes waste products, excess fluids, and toxins from the blood when the kidneys are no longer able to perform these functions effectively. In this process, blood is filtered through a semipermeable membrane, allowing for the selective removal of waste while preserving necessary components like blood cells and proteins. Hemodialysis is typically performed in patients with end-stage renal disease (ESRD) or severe kidney...
Chronic Kidney Disease IV: Nursing Management01:18

Chronic Kidney Disease IV: Nursing Management

Nursing management is essential for preventing complications, maintaining stability, and improving patients' quality of life in chronic kidney disease (CKD). By using a structured approach, nurses help slow CKD progression and support effective patient care​.1. Comprehensive patient assessmentEffective management begins with nurses reviewing the patient’s medical history, and identifying key risk factors like diabetes, hypertension, and nephrotoxic drug use. Nurses assess signs of fluid...